Company intelligence / Profile preview
RadAlliance Therapeutics
San Diego, California, United Statesradalliancetx.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
RadAlliance Therapeutics is a clinical-stage targeted radionuclide therapy biotech focused on precision oncology. Founded in late 2024 and based in San Diego, the company is developing diagnostic and therapeutic nuclear medicines. Its disclosed pipeline includes PSMA-targeted radiopharmaceutical programs for prostate cancer, including an actinium-225 therapeutic candidate and a copper-64 imaging/diagnostic agent. The company appears to be focused on improving tumor retention and efficacy in radioligand therapy for metastatic castration-resistant prostate cancer.
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on RadAlliance Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RadAlliance Therapeutics.